IT1406051B1 - Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. - Google Patents

Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.

Info

Publication number
IT1406051B1
IT1406051B1 ITRM2010A000442A ITRM20100442A IT1406051B1 IT 1406051 B1 IT1406051 B1 IT 1406051B1 IT RM2010A000442 A ITRM2010A000442 A IT RM2010A000442A IT RM20100442 A ITRM20100442 A IT RM20100442A IT 1406051 B1 IT1406051 B1 IT 1406051B1
Authority
IT
Italy
Prior art keywords
hmgb1
detection
biological marker
invasive method
human intestinal
Prior art date
Application number
ITRM2010A000442A
Other languages
English (en)
Italian (it)
Inventor
Salvatore Cucchiara
Laura Stronati
Roberta Vitali
Original Assignee
D M G Italia S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ITRM2010A000442A priority Critical patent/IT1406051B1/it
Application filed by D M G Italia S R L filed Critical D M G Italia S R L
Priority to PCT/IT2011/000276 priority patent/WO2012017466A1/en
Priority to EA201390197A priority patent/EA201390197A1/ru
Priority to AU2011287193A priority patent/AU2011287193B2/en
Priority to CN2011800327624A priority patent/CN103069276A/zh
Priority to CA2807107A priority patent/CA2807107C/en
Priority to US13/814,294 priority patent/US20130137123A1/en
Priority to MX2013001327A priority patent/MX2013001327A/es
Priority to EP11754539.2A priority patent/EP2601525A1/en
Priority to PE2013000131A priority patent/PE20131062A1/es
Priority to BR112013002145A priority patent/BR112013002145A2/pt
Priority to JP2013522346A priority patent/JP2013534313A/ja
Publication of ITRM20100442A1 publication Critical patent/ITRM20100442A1/it
Priority to IL223845A priority patent/IL223845A/en
Priority to CL2013000223A priority patent/CL2013000223A1/es
Application granted granted Critical
Publication of IT1406051B1 publication Critical patent/IT1406051B1/it

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ITRM2010A000442A 2010-08-05 2010-08-05 Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. IT1406051B1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ITRM2010A000442A IT1406051B1 (it) 2010-08-05 2010-08-05 Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
EP11754539.2A EP2601525A1 (en) 2010-08-05 2011-08-01 Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
AU2011287193A AU2011287193B2 (en) 2010-08-05 2011-08-01 Use of HMGB1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
CN2011800327624A CN103069276A (zh) 2010-08-05 2011-08-01 Hmgb1作为炎性肠病病情的生物标志物的用途、其在粪便样品中的非侵入性检测方法及其试剂盒
CA2807107A CA2807107C (en) 2010-08-05 2011-08-01 Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
US13/814,294 US20130137123A1 (en) 2010-08-05 2011-08-01 Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
PCT/IT2011/000276 WO2012017466A1 (en) 2010-08-05 2011-08-01 Use of hmgb1 as' a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
EA201390197A EA201390197A1 (ru) 2010-08-05 2011-08-01 Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого
PE2013000131A PE20131062A1 (es) 2010-08-05 2011-08-01 Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion
BR112013002145A BR112013002145A2 (pt) 2010-08-05 2011-08-01 uso de hmgb1 como um marcador biológico das condições inflamatórias intestinais, método não-invasivo para detecção das mesmas em amostras fecais e respectivo kit
JP2013522346A JP2013534313A (ja) 2010-08-05 2011-08-01 腸の炎症状態の生物学的マーカーとしてのｈｍｇｂ１の使用、糞便サンプル中のｈｍｇｂ１を検出するための非侵襲法およびそのキット
MX2013001327A MX2013001327A (es) 2010-08-05 2011-08-01 Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion.
IL223845A IL223845A (en) 2010-08-05 2012-12-24 Use of 1hmgb as a biomarker of intestinal inflammatory conditions, non-invasive methods for his diagnosis of faecal samples and kit
CL2013000223A CL2013000223A1 (es) 2010-08-05 2013-01-23 Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias , metodo no invasivo para deteccion en muestras fecales y kit para su realizacion.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2010A000442A IT1406051B1 (it) 2010-08-05 2010-08-05 Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.

Publications (2)

Publication Number Publication Date
ITRM20100442A1 ITRM20100442A1 (it) 2012-02-06
IT1406051B1 true IT1406051B1 (it) 2014-02-06

Family

ID=43739596

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM2010A000442A IT1406051B1 (it) 2010-08-05 2010-08-05 Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.

Country Status (14)

Country Link
US (1) US20130137123A1 (enExample)
EP (1) EP2601525A1 (enExample)
JP (1) JP2013534313A (enExample)
CN (1) CN103069276A (enExample)
AU (1) AU2011287193B2 (enExample)
BR (1) BR112013002145A2 (enExample)
CA (1) CA2807107C (enExample)
CL (1) CL2013000223A1 (enExample)
EA (1) EA201390197A1 (enExample)
IL (1) IL223845A (enExample)
IT (1) IT1406051B1 (enExample)
MX (1) MX2013001327A (enExample)
PE (1) PE20131062A1 (enExample)
WO (1) WO2012017466A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019016753A1 (en) 2017-07-20 2019-01-24 Laura Stronati USE OF GELSOLIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INTESTINAL INFLAMMATORY DISEASES
WO2019016719A1 (en) 2017-07-20 2019-01-24 Laura Stronati USE OF RHO GDP DISSOCIATION INHIBITORY PROTEIN 2 AS A DIAGNOSTIC AND PROGNOSTIC MARKER FOR INFLAMMATORY BOWEL DISEASES

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968443B1 (en) 2013-03-15 2021-09-29 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
EP3094973B1 (en) 2013-11-07 2020-07-29 Diagnodus Limited Biomarkers
EP3143037B1 (en) 2014-05-16 2021-06-23 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
CN113563423A (zh) 2014-07-17 2021-10-29 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US20200064357A1 (en) * 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
BR112019023772A2 (pt) 2017-05-12 2020-06-09 Evonik Operations Gmbh método para detectar doenças induzidas por c. perfringens em animais e kit de diagnóstico
EP4501952A3 (en) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US12031991B2 (en) 2018-03-02 2024-07-09 Evonik Operations Gmbh In vitro method for detecting intestinal barrier failure in animals
CN109030817A (zh) * 2018-07-04 2018-12-18 长沙都正医学检验有限责任公司 Hmgb1检测试剂盒及其制备方法
EP3894863B1 (en) 2018-12-14 2022-11-23 Evonik Operations GmbH In vitro method for detecting avian intestinal dysbiosis
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
BR112022014011A2 (pt) 2020-01-15 2022-12-20 Janssen Biotech Inc Inibidores peptídicos de receptor de interleucina-23 e seu uso no tratamento de doenças inflamatórias
MX2022008741A (es) 2020-01-15 2022-10-03 Janssen Biotech Inc Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
WO2022109328A1 (en) 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
CN116973572B (zh) * 2023-06-02 2025-03-07 东南大学附属中大医院 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0964250B1 (en) * 1996-07-17 2007-06-27 Kaneka Corporation Diagnostic drugs for autoimmune diseases
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7700307B2 (en) * 2003-03-08 2010-04-20 Auvation Limited Mitochondrial stress-70 protein markers for colorectal cancer
AU2005333602B2 (en) * 2004-10-22 2012-04-12 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
WO2008075788A1 (ja) * 2006-12-20 2008-06-26 Shino-Test Corporation ヒトｈｍｇｂ１と特異的に結合する鳥類由来の抗体、ヒトｈｍｇｂ１の免疫学的測定方法及びヒトｈｍｇｂ１の免疫学的測定試薬
EA201000131A1 (ru) * 2007-08-02 2010-08-30 АйЭсЭс ИММЬЮН СИСТЕМ СТИМУЛЕЙШН АБ Диагностика, определение стадии и мониторинг воспалительного заболевания кишечника
WO2009114756A2 (en) * 2008-03-14 2009-09-17 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019016753A1 (en) 2017-07-20 2019-01-24 Laura Stronati USE OF GELSOLIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INTESTINAL INFLAMMATORY DISEASES
WO2019016719A1 (en) 2017-07-20 2019-01-24 Laura Stronati USE OF RHO GDP DISSOCIATION INHIBITORY PROTEIN 2 AS A DIAGNOSTIC AND PROGNOSTIC MARKER FOR INFLAMMATORY BOWEL DISEASES

Also Published As

Publication number Publication date
AU2011287193A1 (en) 2013-06-13
CA2807107A1 (en) 2012-02-09
US20130137123A1 (en) 2013-05-30
CN103069276A (zh) 2013-04-24
WO2012017466A8 (en) 2013-07-11
JP2013534313A (ja) 2013-09-02
AU2011287193B2 (en) 2015-08-13
WO2012017466A1 (en) 2012-02-09
CL2013000223A1 (es) 2014-03-28
EP2601525A1 (en) 2013-06-12
PE20131062A1 (es) 2013-10-16
EA201390197A1 (ru) 2013-06-28
ITRM20100442A1 (it) 2012-02-06
IL223845A (en) 2016-06-30
BR112013002145A2 (pt) 2016-05-24
MX2013001327A (es) 2013-03-08
CA2807107C (en) 2017-01-03

Similar Documents

Publication Publication Date Title
IT1406051B1 (it) Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
BRPI0924177A2 (pt) Polipeptídeos, seu método de preparação, sua composição, sequência de nucleotídeo e uso
BRPI0912807A2 (pt) produto de aço inoxidável, uso do produto e método de sua fabricação
DOP2011000274A (es) Proteinas de union a il-17
BRPI1012340A (pt) proteínas de ligação específica e usos das mesmas
LTC2358756I2 (lt) Žmogaus antikūnai, pasižymintys dideliu giminingumu pcsk9
BRPI0911297A2 (pt) composição e métodos para preparo e uso das mesmas
BRPI0820556A2 (pt) Bactéria e métodos para uso das mesmas
PT2426148E (pt) Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
BRPI0919438A2 (pt) mistura de poliésteres, e, uso das misturas de poliésteres
IL212856A (en) Human antibodies against human tissue factor, conjugates and uses thereof
BRPI0914801A2 (pt) método para detectar o grupo sanguíneo abo/rh/mn humano, e, kit
BR112012003792A2 (pt) gel tópico, e, uso do gel tópico.
BRPI1010304A2 (pt) dispositivo de espectroscopia óptica para detecção de glicose no sangue não invasiva e método de uso associado.
BRPI1011655A2 (pt) uso de lcat para tratar anemia e disfunção de glóbulos vermelhos
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI1012990A2 (pt) "dispositivo de monitoramento de analito e métodos de uso"
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BRPI1014914A2 (pt) Composição contendo trehalulose, sua preparação e uso
AP2011005665A0 (en) Detection of HIV-related proteins in urine.
BRPI1012924A2 (pt) derivados de amilóide p de soro e sua preparação e uso.
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112012001043A2 (pt) tinturas fluorescentes e uso das mesmas
BRPI1006733A2 (pt) kit para formação de imagem médica marcada e/ou produtos terapêuticos, agente de pré-marcação, sonda de formação de imagem, sonda terapêutica e método
BR112012016229A2 (pt) método para melhorar a sobrevida livre de progressão, método in vitro, kit, uso de um oligonucleotídeo ou polipetídeo e uso de bevacizumab